Company: GHRS
Filing Date: 2025-07-29
Form Type: 20-F/A
Source: 0001140361-25-027850
Chunk: 268

Company: GH Research PLC
Filing Date: 2025-07-29
Form: 20-F/A
Chunk 268
---
 the year           |     |      |     |              |  78,420 |   |     |       | 165,955 |   |     |       |  276,776 |   |
| Impact of foreign exchange on cash and cash equivalents          |     |      |     |              |    (175 | ) |     |       |     105 |   |     |       |       66 |   |
| Cash and cash equivalents at the end of the year                 |     |      |     |              | 100,791 |   |     |       |  78,420 |   |     |       |  165,955 |   |

The accompanying notes to the consolidated financial statements are an integral part of these consolidated financial statements. F-6 Table of Contents

| GH RESEARCH PLC                                |
| NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS |

1.Corporate information GH Research PLC (the “Company”) was incorporated on March 29, 2021. The registered office of the Company is located at Joshua Dawson House, DawsonStreet, Dublin 2, Ireland. The Company controls one wholly-owned subsidiary: GH Research Ireland Limited, which was incorporated in Dublin, Ireland on October 16, 2018. The Company and its subsidiary form the GH Research Group (the “Group” or “GH Research”). The Group is a clinical-stage biopharmaceutical company dedicated to transforming the lives of patients by developing a practice-changing treatment in depression. Its initial focus is on developing the novel and proprietary mebufotenin therapies for the treatment of patients with Treatment Resistant Depression, or TRD. Its portfolio currently includes GH001, a proprietary inhalable mebufotenin product candidate and GH002, a proprietary intravenous mebufotenin product candidate. These consolidated financial statements were presented to the Board of Directors and approved by them for issue on February 27, 2025.

2.Basis of preparation, significant judgments, and accounting policies Basis of preparation Compliance with IFRS Accounting Standards The consolidated financial statements for the year ended December 31, 2024, have been prepared in accordance with IFRS Accounting Standards as adopted by the International Accounting Standards Board (“IASB”). These consolidated financial statements are presented in U.S. dollar (“USD” or “$”), which is the Company’s functional currency and the Group’s presentation currency. The financial statements have been prepared under the historical cost convention aside from the measurement at fair value of all investments in money